Comparing Your Options

Every page in this hub ends at the same question, so this page faces it directly: of all of it — the drugs, the needles, the devices, the therapies — what actually works? The honest answer is better than the marketing answer, but it requires a reframe. Read the trial literature whole and its clearest finding is that no treatment wins across the board: nearly everything helps modestly on average, and the real differences between options lie elsewhere — in how certain the evidence is, how long benefits last, how safe the option is, and which pain mechanism it fits. This page maps those differences the way the field sees them — and teaches the reading skills to weigh any option, or any claim, yourself.

The map

Two regions of the map deserve your attention. The high-certainty shore on the right holds exercise, active rehabilitation, and the behavioral therapies — benefits that are modest on average but proven across the most trials, durable, and essentially risk-free, which is why guidelines start there. The selection-dependent heights in the upper middle hold the stimulators and ablation and the nerve-pain drugs: larger effects, but only in the right patient — a stimulator transforms a matched candidate and does nothing for anyone else. Everything about using this map well follows from one habit: never ask “does it work?” without adding for which mechanism, in whom, for how long, at what risk.

Four rules for reading the evidence

One: averages hide responders. A modest mean effect usually blends people who improved substantially with people who didn’t improve at all. The average is not your forecast — it is a reason to run fair trials and find your responders’ list. Two: certainty and size are different axes. Exercise is certain and modest; plenty of heavily marketed options are uncertain and loud. When forced to choose, the field chooses certainty — you can build on what you can trust. Three: mechanism fit beats potency— the lesson of the medications map, and it generalizes to every row of the toolbox. Four: durability and safety multiply. A modest effect that is safe and lasts compounds year over year; a strong effect that is brief or costly to the body does not. This is the quiet math behind why guidelines keep putting the unglamorous options first.

The stacking strategy

Those four rules converge on the strategy this site keeps arriving at from every direction: stack modest wins. Chronic pain care fails most often not because options failed but because each was tried alone, judged “only modest,” and abandoned before the next audition. The alternative is additive: movement rebuilt with pacing, sleep repaired, a mechanism-matched medication kept because it earns its place, a procedure’s window spent on rehabilitation. Effects from different mechanisms add; their side effects mostly don’t. No single layer looks dramatic. The stack changes trajectories.

Where the long-term opioid evidence landed

One comparison on the map deserves its own paragraph, because a rigorous trial finally ran it. The SPACE trial randomized veterans with chronic back pain or hip and knee arthritis to opioid or non-opioid medication strategies and followed them for a year: the opioid arm ended no better on function, slightly worse on pain, with more side effects. That is not a verdict on every use of these medicines — cancer pain is a different conversation, and people already on long-term therapy deserve careful individualized care, never abandonment. It is a verdict on the old assumption that the strongest painkiller must be the strongest treatment for chronic pain. For anyone whose use has come to feel like its own problem, the SAMHSA helpline — 1-800-662-4357 — is free, confidential, and always open.

The complementary aisle

Complementary options divide cleanly on the certainty axis. Acupuncture has been examined about as rigorously as a hands-on therapy can be — an individual-patient- data meta-analysis of dozens of trials — and shows real benefits beyond sham for several chronic pain conditions: small on average, persistent, low-risk. As an adjunct for someone drawn to it, that is a defensible bet. Supplements are mostly the opposite corner: unregulated products, thin trials, and genuine interaction potential — worth naming to your clinician and pharmacist rather than filing under harmless. The four claim-reading questions at the end of this page apply with extra force anywhere a product is sold outside medicine’s evidence machinery.

Running a fair trial on yourself

The map narrows your options; personal trials decide them. The method is simple and rarely followed: change one thing at a time; define success as a functional target — the walk, the workday, the night’s sleep — not only a pain score; agree on a time window with your clinician; keep a simple diary; and decide in advance what result means continue versus stop. Done this way, even a “failed” trial is a win — it retires an option with confidence and clears the stage for the next.

Reading a claim like the field does

Finally, the skill that protects everything else. For any treatment claim, ask: compared with what? In whom? For how long? And who profits from my yes? The red flags repeat across every era of pain marketing: one remedy claimed to work for every kind of pain, testimonials doing the work of trials, mechanisms too secret to explain, and the language of certainty where medicine speaks in probabilities. The green flags are just as consistent — and they are this site’s own standard: evidence named, limits volunteered, and a clear statement of who an option is for. Building your particular stack from this map is exactly the craft of pain medicine, and finding pain care near you is where to take it.